MA30522B1 - Composes ayant une activite au niveau du transporteur glyt1 - Google Patents

Composes ayant une activite au niveau du transporteur glyt1

Info

Publication number
MA30522B1
MA30522B1 MA31488A MA31488A MA30522B1 MA 30522 B1 MA30522 B1 MA 30522B1 MA 31488 A MA31488 A MA 31488A MA 31488 A MA31488 A MA 31488A MA 30522 B1 MA30522 B1 MA 30522B1
Authority
MA
Morocco
Prior art keywords
activity
compounds
transporter glyt1
benzamide
trifluoromethyl
Prior art date
Application number
MA31488A
Other languages
English (en)
Inventor
Claire Louise Anderton
David Clapham
Trevor Raymond Keel
Leanda Jane Kindon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30522B1 publication Critical patent/MA30522B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Dérivés de pyrrolidine ayant une activité au niveau du transporteur GlyTl Les sels consistant en succinate et napadisylate et produits de solvatation de napadisylate de 2 - (méthyloxy ) -N- [2-méthyl-l-phényl-2- (1-pyrrolidinyl) -propyl]-4,6-bis(trifluorométhyl)benzamide,6-bis(trifluoro-méthyl)benzamide, et leurs utilisations dans le traitement de troubles en rapport avec le transporteur GlyTl, tels que la schizophrénie, sont décrits.
MA31488A 2006-06-22 2008-12-19 Composes ayant une activite au niveau du transporteur glyt1 MA30522B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds

Publications (1)

Publication Number Publication Date
MA30522B1 true MA30522B1 (fr) 2009-06-01

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31488A MA30522B1 (fr) 2006-06-22 2008-12-19 Composes ayant une activite au niveau du transporteur glyt1

Country Status (23)

Country Link
US (1) US20080070973A1 (fr)
EP (1) EP2041082B1 (fr)
JP (1) JP2009541261A (fr)
KR (1) KR20090019847A (fr)
CN (1) CN101506156A (fr)
AR (1) AR061554A1 (fr)
AT (1) ATE444288T1 (fr)
AU (1) AU2007263058A1 (fr)
BR (1) BRPI0713311A2 (fr)
CA (1) CA2655399A1 (fr)
CL (1) CL2007001808A1 (fr)
CR (1) CR10498A (fr)
DE (1) DE602007002642D1 (fr)
EA (1) EA200970044A1 (fr)
ES (1) ES2333918T3 (fr)
GB (1) GB0612420D0 (fr)
IL (1) IL195633A0 (fr)
MA (1) MA30522B1 (fr)
NO (1) NO20085412L (fr)
PE (1) PE20080380A1 (fr)
TW (1) TW200817322A (fr)
WO (1) WO2007147831A1 (fr)
ZA (1) ZA200810009B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
JP2010530397A (ja) * 2007-06-20 2010-09-09 グラクソ グループ リミテッド アミド形成の改善方法
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
ES2928785T3 (es) 2017-10-13 2022-11-22 Treeway Tw001 B V Sal de edaravona

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Also Published As

Publication number Publication date
CL2007001808A1 (es) 2008-01-18
DE602007002642D1 (de) 2009-11-12
IL195633A0 (en) 2009-09-01
ES2333918T3 (es) 2010-03-02
PE20080380A1 (es) 2008-05-31
AR061554A1 (es) 2008-09-03
BRPI0713311A2 (pt) 2012-03-06
NO20085412L (no) 2009-01-22
CA2655399A1 (fr) 2007-12-27
WO2007147831A1 (fr) 2007-12-27
EA200970044A1 (ru) 2009-04-28
EP2041082A1 (fr) 2009-04-01
EP2041082B1 (fr) 2009-09-30
AU2007263058A1 (en) 2007-12-27
TW200817322A (en) 2008-04-16
GB0612420D0 (en) 2006-08-02
ATE444288T1 (de) 2009-10-15
JP2009541261A (ja) 2009-11-26
CN101506156A (zh) 2009-08-12
KR20090019847A (ko) 2009-02-25
CR10498A (es) 2009-03-20
US20080070973A1 (en) 2008-03-20
ZA200810009B (en) 2009-11-25

Similar Documents

Publication Publication Date Title
MA30522B1 (fr) Composes ayant une activite au niveau du transporteur glyt1
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
MA29354B1 (fr) Derives de cyclopentapyridine et tetrahydroquinoleine.
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA31683B1 (fr) Composes et procedes pour moduler fxr
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
MA31580B1 (fr) Derives de bicyclolactames substitués
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
MA33451B1 (fr) Dérivés d'imidazolidin-2-one 1,3-disubstitués en tant qu'inhibiteurs de cyp 17
FR2903618B1 (fr) Agent de dispersion et/ou d'aide au broyage pour dispersion et suspension aqueuse de matieres minerales, dispersion et suspension obtenues et leurs utilisations.
GT200500309A (es) Derivados de sulfonilbencilimidazol
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
Nowak et al. Discovery and initial optimization of 5, 5′-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones